Humane Genomics Inc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Humane Genomics Inc - overview
Established
2019
Location
New York, NY, US
Primary Industry
Biotechnology
About
Based in New York, US, and founded in 2019 by CEO Peter Weijmarshausen, Chad Moles, and Andrew Hessel, Humane Genomics Inc operates as a biotechnology company that focuses on the development of a virus development platform that develops artificial viruses to cure diseases. In February 2025, Humane Genomics Inc raised an undisclosed amount of seed funding led by new investor Union Square Ventures. The company develops precision-designed oncolytic viral therapies, utilizing synthetic biology to engineer viruses that can effectively kill cancer cells. Using DNA synthesis and lab robotics, the company's platform creates an oncolytic virus that is customized for various tumor types using a proprietary design and digital library.
This allows patients to receive safe and effective therapies for cancer cells taken from their biopsy. In addition, the technology used by the company can 3D print or synthesize DNA based on a computer file. The company will use the February 2025 funding to support its expansion plans.
Current Investors
2048 Ventures, Y Combinator, Union Square Ventures
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.humanegenomics.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.